Nearly 70% of ovarian cancer (OC) patients experience recurrence within the first 2 years after initial treatment. Emerging evidence indicates that long non-coding RNAs (lncRNAs) play a pivotal role in the pathogenesis of OC progression, resistance to therapy and recurrent OC (ROC). Transcriptome profiling studies have reported differential expression patterns of lncRNAs in OC which are related to increased cell invasion, metastasis and drug resistance. In this review, we highlighted the roles of lncRNAs in OC progression and outlined the potential molecular mechanisms by which lncRNAs impact on ROC. Recent advances using lncRNAs as potential biomarkers for screening, detection, prediction, response to therapy and as therapeutic targets are discussed.

近 70% 的卵巢癌 (OC) 患者在初始治疗后的前 2 年内会复发。新出现的证据表明，长链非编码 RNA ( lncRNAs ) 在 OC 进展、治疗抵抗和复发性 OC (ROC) 的发病机制中起着关键作用。转录组分析研究报告了 OC中lncRNA 的差异表达模式，这与细胞侵袭、转移和耐药性增加有关。在这篇综述中，我们强调了lncRNAs在 OC 进展中的作用，并概述了lncRNAs影响 ROC的潜在分子机制。使用lncRNA 的最新进展 作为筛选、检测、预测、治疗反应的潜在生物标志物以及作为治疗靶点进行了讨论。